Want to see AVIR full AI Analyst Report?
AVIR Stock Chart & Stats
$4.73
-$0.02(-0.42%)
At close: 4:00 PM EDT
$4.73
-$0.02(-0.42%)
Day’s Range― - ―
52-Week Range$2.78 - $6.45
Previous Close$4.82
Volume381.47K
Average Volume (3M)331.21K
Market Cap
$441.93M
Enterprise Value$153.19
Total Cash (Recent Filing)$219.47M
Total Debt (Recent Filing)$424.00K
Price to Earnings (P/E)―
Beta0.67
Next Earnings
Nov 05, 2026EPS Estimate
-0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.08
Shares Outstanding80,204,700
10 Day Avg. Volume266,515
30 Day Avg. Volume331,208
Financial Highlights & Ratios
PEG Ratio0.61
Price to Book (P/B)1.06
Price to Sales (P/S)0.00
P/FCF Ratio-2.20
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$7.00Price Target Upside47.99% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.93
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Phase 3 Clinical ValidationSuccessful Phase 3 results materially reduce clinical risk for the lead HCV program. Non-inferior efficacy and comparable safety provide a credible foundation for regulatory review and potential commercialization, subject to the remaining global study.
Global Regulatory ProgressFull enrollment and a defined readout-to-NDA timeline show substantial program execution and reduce development uncertainty. A global Phase 3 package could support broader labeling and create a clear path toward a commercial product.
Commercial Opportunity And ReadinessStrong physician interest, supply preparation, and adherence-oriented packaging indicate that Atea is building commercial capabilities before approval. These assets may improve launch execution and support adoption of a convenient regimen in an under-treated HCV market.
Bears Say
No Recurring Product RevenueAtea has not established a recurring commercial revenue base, leaving its financial outlook dependent on future regulatory success and launch execution. Persistent losses also limit visibility into when the business can become self-funding.
High Cash Burn And Shrinking EquityMaterial operating burn and declining equity show that development is consuming capital rather than generating it. This raises dependence on financing or spending reductions and could constrain investment in commercialization and pipeline expansion.
Funding And Regulatory Timing RiskThe stated runway may not fully cover the period through launch, especially if regulatory review or development spending extends. Additional financing could create dilution, while a delayed or unfavorable C-FORWARD result would materially defer revenue.
Atea Pharmaceuticals News
AVIR FAQ
What was Atea Pharmaceuticals’s price range in the past 12 months?
Atea Pharmaceuticals lowest stock price was $2.78 and its highest was $6.45 in the past 12 months.
What is Atea Pharmaceuticals’s market cap?
Atea Pharmaceuticals’s market cap is $441.93M.
When is Atea Pharmaceuticals’s upcoming earnings report date?
Atea Pharmaceuticals’s upcoming earnings report date is Nov 05, 2026 which is in 71 days.
How were Atea Pharmaceuticals’s earnings last quarter?
Atea Pharmaceuticals released its earnings results on Aug 12, 2026. The company reported -$0.41 earnings per share for the quarter, beating the consensus estimate of -$0.555 by $0.145.
Is Atea Pharmaceuticals overvalued?
According to Wall Street analysts Atea Pharmaceuticals’s price is currently Undervalued.
Does Atea Pharmaceuticals pay dividends?
Atea Pharmaceuticals does not currently pay dividends.
What is Atea Pharmaceuticals’s EPS estimate?
Atea Pharmaceuticals’s EPS estimate is -0.51.
How many shares outstanding does Atea Pharmaceuticals have?
Atea Pharmaceuticals has 80,204,700 shares outstanding.
What happened to Atea Pharmaceuticals’s price movement after its last earnings report?
Atea Pharmaceuticals reported an EPS of -$0.41 in its last earnings report, beating expectations of -$0.555. Following the earnings report the stock price went up 0.198%.
Which hedge fund is a major shareholder of Atea Pharmaceuticals?
Currently, no hedge funds are holding shares in AVIR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Atea Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.00 (47.99% Upside)
$7.00 (47.99% Upside)
Blogger Sentiment
Bullish
AVIR Sentiment 100%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Increased
By 16.1K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.37%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-40.68%
Trailing 12-Months
Company Description
Atea Pharmaceuticals
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
AVIR Company Deck
AVIR Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed several material positive developments: a successful Phase 3 (CBEYOND) meeting primary and secondary endpoints with a favorable safety profile, rapid global enrollment and a clear development/regulatory path (C‑FORWARD readout early Q1 2027 and potential NDA in Q2 2027), a promising commercial proposition supported by market research, manufacturing readiness, and a new HEV first‑in‑human program. Offsetting risks include modest numeric SVR differences versus the comparator despite non‑inferiority, persistent adherence and loss‑to‑follow‑up challenges in real‑world populations, finite cash runway through 2027 (raising potential funding needs), and policy/pricing and regulatory timing uncertainties. Overall, the positives—clinical proof of concept, program momentum, and commercial preparedness—outweigh the headwinds, though execution and timing risks remain.View all AVIR earnings summariesAVIR Stock 12 Month Forecast
Average Price Target
$7.00
▲(47.99% Upside)
Technical Analysis
Ownership Overview
11.27% Insiders
16.72% Mutual Funds
20.79% Other Institutional Investors
39.92% Public Companies and
Individual Investors